A multicentre phase II trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma.

Trial Profile

A multicentre phase II trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 20 Apr 2016 Results (retrospective analysis, n = 34) assessing response to anti-PD-1/PD-L1 therapies post IT-pIL12-EP presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 17 Mar 2016 According to OncoSec media release, new clinical data will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting.
    • 02 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top